Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Financing Activities (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Cash from Financing Activities readings, the most recent being $64.1 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 1386.32% to $64.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.5 million, a 268.25% increase, with the full-year FY2025 number at -$26.6 million, up 3.65% from a year prior.
  • Cash from Financing Activities hit $64.1 million in Q4 2025 for Enanta Pharmaceuticals, up from -$8.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $199.9 million in Q2 2023 to a low of -$8.3 million in Q3 2025.
  • Median Cash from Financing Activities over the past 5 years was $139000.0 (2022), compared with a mean of $11.5 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 4751.33% in 2023 and later crashed 31269.57% in 2024.
  • Enanta Pharmaceuticals' Cash from Financing Activities stood at $9.6 million in 2021, then crashed by 96.88% to $301000.0 in 2022, then plummeted by 2541.86% to -$7.4 million in 2023, then soared by 32.16% to -$5.0 million in 2024, then surged by 1386.32% to $64.1 million in 2025.
  • The last three reported values for Cash from Financing Activities were $64.1 million (Q4 2025), -$8.3 million (Q3 2025), and -$6.4 million (Q2 2025) per Business Quant data.